Oncology Pharm
  1. Bleomycin
  2. Dactinomycin, Actinomycin D
  3. Doxorubicin, Daunorubicin
  4. Azathioprine, 6-MP
  5. Cladribine
  6. Cytarabine
  7. Busulfan
  8. Cyclophosphamide, Ifosfamide
  9. Nitrosoureas
  10. Paclitaxel
  11. Vincristine, Vinblastine
  12. Cisplatin, Carboplatin, Oxaliplatin
  13. Etoposide, Teniposide
  14. Irinotecan, Topotecan
  15. Bevacizumab
  16. Erlotinib
  17. Cetuximab, Panitumumab
  18. Imatinib, Dasatinib
  19. Rituximab
  20. Bortezomib, Carfilzomib
  21. Trastuzumab
  22. Dabrafenib, Vemurafenib
  23. Raloxifene and Tamoxifen
  24. Hydroxyurea
  25. Procarbazine


Hydroxyurea is an antimetabolite drug that inhibits RNR, or ribonucleotide reductase. RNR is an enzyme that plays a role in the conversion of ribonucleotides to deoxyribonucleotides, so by inhibiting RNR, hydroxyurea decreases DNA synthesis and halts the cell cycle in the S phase. This property is particularly useful in targeting and preventing the growth of rapidly dividing cells, which is why hydroxyurea is used to treat myeloproliferative disorders. Additionally, hydroxyurea is used in the treatment of sickle cell disease. Hydroxyurea increases fetal hemoglobin, which is more resistant to sickling than adult hemoglobin.

Key Points

  • Hydroxyurea
    • Mechanism
      • Inhibits ribonucleotide reductase (RNR)
        • Reduces DNA synthesis by inhibiting Pyrimidine Synthesis
        • S-phase specific
    • Clinical use
      • Myeloproliferative disorders
        • E.g. CML, polycythemia vera
      • Sickle cell anemia
        • Via increased fetal hemoglobin (HbF)
          • Mechanism is not understood but HbF is less prone to sickling than adult Hb